The FDA has approved the Idylla CDx MSI test — a fully automated, “sample-to-result” companion diagnostic — for patients with colorectal cancer, according to a press release.

The test, developed by Biocartis in partnership with Bristol Myers Squibb, helps identify patients with microsatellite instability-high (MSI-H) CRC who may benefit from treatment with nivolumab (Opdivo, Bristol Myers Squibb) alone or in combination with ipilimumab (Yervoy, Bristol Myers Squibb).

The FDA has approved the Idylla CDx MSI test — a fully automated, “sample-to-result” companion diagnostic — for patients with colorectal cancer.

“The approval of this new MSI companion diagnostic for patients with colorectal cancer is a meaningful achievement from our collaboration with Biocartis and a strong reflection

See Full Page